🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against superbug strains of the bacteria, according to scientists.

An International Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting in excess of 82 million new cases per year. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Global Access

As per results published in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The study enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Clinicians directly involved have expressed hope. The availability of a easy-to-administer therapy such as this is described as a "game-changer" for public health efforts. This is viewed as essential to lessen the impact of the infection for patients and to prevent the spread of untreatable gonorrhoea worldwide.